5. Conclusions
Despite the small number of patients, the evidence reported in the
present analysis confirms that the clinical burden of DDIs in SARS-CoV-2
inpatients is relevant. Moreover, the risk of unexpected and uncommon
ADRs, such those referred to psychiatric disorders, was highlighted. In
this population, COVID-19 treatments should be used with extreme
caution, especially in fragile and polymedicated patients. Although
living in the context of a global emergency and looking for an effective
therapeutic treatment, drug safety should never be overlooked,
especially in the presence of DDIs.